(firstQuint)Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects.

 This is a phase I dose escalation study.

 To meet the clinical objectives, we are using a two-part approach.

 In part I, 4 subjects are injected 0.

5mg dose of DA-3091 or placebo(Single/Subcutaneous Injection).

 After completion of part I study, we are reporting data about safety to IDMC.

 In part II, 8 subjects per group are injected 1mg, 2mg, 4mg of DA-3091 or placebo through dose escalating protocol.

 The ratio of DA-3091 and placebo is 3:1.

.

 Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects@highlight

This Phase I clinical study is to evaluate the safety and tolerance of DA-3091 and to characterize the pharmacokinetic/pharmacodynamic of DA-3091 in healthy male subjects